More than 21 million adults in the U.S. experience major depression each year. For decades, treatment relied on trial and error—cycling through medications and hoping something would work. But that’s beginning to change.
We’re entering a new era: one where treatment is informed by biology, not just symptoms. From tricyclics to ketamine, from SSRIs to psychedelics, here’s how the field has evolved—and what comes next.
The First Wave: Tricyclics and MAOIs
In the 1950s and ‘60s, the first generation of antidepressants emerged—tricyclics and monoamine oxidase inhibitors (MAOIs). While they were effective for some, they also came with serious side effects and strict dietary restrictions, limiting their use.
The SSRI Revolution
The approval of Prozac (fluoxetine) in 1987 changed the game. SSRIs offered similar efficacy with fewer side effects and quickly became the standard. They also helped bring depression into broader public awareness, reducing stigma and making treatment more accessible.
Beyond Serotonin: Expanding the Toolkit
By the 2000s, combining medications became common. SNRIs, atypical antipsychotics, and augmentation strategies were introduced to address cases that didn’t respond to first-line treatments. But while options grew, personalization didn’t—treatment plans were still mostly guesswork.
A Turning Point: Ketamine and Psychedelics
In 2019, the FDA approved esketamine, a fast-acting antidepressant targeting glutamate receptors. Unlike traditional meds that could take weeks, esketamine often worked within hours. Around the same time, psychedelics like psilocybin and MDMA re-entered the conversation, backed by rigorous trials showing long-term effects after just one or two sessions.
What’s Next: Precision Psychiatry
The future of depression treatment lies in personalization. With advances in neuroimaging, biomarkers, and AI, we’re moving toward a world where clinicians can match patients with the right treatment from day one. No more trial-and-error. Just targeted care that works.
To be notified when posts like this are published, subscribe here: https://www.withpower.com/hub
Related posts
Subscribe to Power's Newsletter
Stay ahead with a new patient recruitment insight every week.